Mixed CB1/CB2 agonist, WIN-55212,2 decreased the progression and metastasis of B16F10 melanoma cells in mice after subcutaneous and intra-plantar implantation, respectively (Blázquez et al., 2006). The gene discussed is CNR1; the disease is melanoma.